Investment Analysts’ updated eps estimates for Saturday, January 6th:

Mistras Group (NYSE:MG) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Mistras Group, Inc. is a global provider of technology-enabled, non-destructive testing (NDT) solutions used to evaluate the structural integrity of critical energy, industrial and public infrastructure. The Company delivers a portfolio of solutions, ranging from routine NDT inspections to plant-wide asset integrity assessment and management solutions. The Company serves a global customer base, including companies in the oil and gas, fossil and nuclear power generation and transmission, public infrastructure, chemicals, aerospace and defense, transportation, primary metals and metalworking, pharmaceuticals and food processing industries. “

Miragen Therapeutics (NASDAQ:MGEN) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. “

Moog (NYSE:MOG.A) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $98.00 price target on the stock. According to Zacks, “Moog, Inc. is a designer, manufacturer and integrator of precision motion, fluid controls and systems for applications in aerospace, defense and industrial markets. It operates through five segments: Aircraft Controls, Space and Defense Controls, Industrial Systems, Components and Medical Devices. The Aircraft Controls segment designs, manufactures and integrates primary and secondary flight controls for military and commercial aircraft and provides aftermarket support. The Space and Defense Controls segment provides controls for satellites and space vehicles, armored combat vehicles, tactical and strategic missiles, security and surveillance. The Industrial Systems segment designs and manufactures electric pitch controls and blade monitoring systems for wind turbines and also supplies electromechanical motion simulation bases. Its Components segment offers slip rings, fiber optic rotary joints and handpieces product line. Its Medical Devices segment focuses on infusion therapy & enteral clinical nutrition. “

Medical Transcription Billing (NASDAQ:MTBC) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Medical Transcription Billing, Corp. is a healthcare information technology company. It engages in providing integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company offers revenue cycle, practice management services, patient scheduling, automated appointment reminders, e-prescribing, lab connectivity, and real-time insurance eligibility verification. Transcription Billing, Corp. is headquartered in Somerset, New Jersey. “

Myers Industries (NYSE:MYE) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $23.00 target price on the stock. According to Zacks, “Myers Industries, Inc. is an international manufacturer of polymer products for industrial, agricultural, automotive, commercial, and consumer markets. The Company is also the largest wholesale distributor of tools, equipment, and supplies for the tire service and undervehicle repair industry in the United States. “

Neogen (NASDAQ:NEOG) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. The firm currently has $69.00 target price on the stock. According to Zacks, “Neogen Corporation develops, manufactures and markets a diverse line of products dedicated to food and animal safety. The Company’s Lansing, Mich.-based Food Safety Division develops and markets dehydrated culture media, and rapid diagnostic test kits to detect foodborne bacteria, spoilage organisms, mycotoxins, food allergens, genetic modifications, drug residues, plant diseases, and sanitation concerns. Neogen’s is the leading global provider of DNA testing for animal agribusiness and veterinary medicine. Neogen understands that its customers face serious consequences if their products are contaminated with any of a number of well-established or emerging threats, including dangerous bacteria, natural toxins, veterinary drug residues, unlabeled food allergens, rodent filth, sanitation concerns, broken veterinary needles or other contaminants. “

National General (NASDAQ:NGHC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “National General Holdings Corp. is a specialty personal lines insurance holding company. The Company, through its subsidiaries, provides personal and commercial automobile insurance, recreational vehicle and motorcycle insurance, supplemental health insurance products and other niche insurance products. It operates in two segments, Property and Casualty and Accident and Health. The Property and Casualty segment offers standard and preferred automobile and sub-standard automobile insurance policies; Recreational vehicle insurance policies; commercial automobile insurance policies; and motorcycle insurance policies for various types of motorcycles, as well as golf carts and all-terrain vehicles. The Accident and Health segment provides accident and non-major medical health insurance products. National General Holdings Corp. is headquartered in New York. “

Nantkwest (NASDAQ:NK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $5.00 price target on the stock. According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “

Buckingham Research began coverage on shares of Nike (NYSE:NKE). Buckingham Research issued a buy rating and a $72.00 target price on the stock.

Newpark Resources (NYSE:NR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Newpark Resources, Inc. and its subsidiaries, provides products and services primarily to the oil and gas exploration and production industry. The company operates through two segments, Fluids Systems and Mats and Integrated Services. The Fluids Systems segment offers drilling fluids products and technical services for technical drilling projects involving complex subsurface conditions, including horizontal, directional, geologically deep or deep water drilling. This segment also grinds barite and other industrial minerals. The Mats and Integrated Services segment provides composite mat rentals, well site construction, and related site services to oil and gas customers at well, production, transportation, and refinery locations. The company operates in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. “

Intec Pharma (NASDAQ:NTEC) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $7.75 target price on the stock. According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “

NV5 Global (NASDAQ:NVEE) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $58.00 price target on the stock. According to Zacks, “NV5 Holding Inc. offers professional, technical consulting and certification solutions for public and private sector. The company focuses on business services which include construction quality assurance, infrastructure engineering, energy services, program management, and environmental services. It operates in California, Colorado, Utah, Florida and New Jersey. NV5 Holding Inc. is headquartered in Hollywood, Florida. “

NexPoint Residential Trust (NYSE:NXRT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $30.00 target price on the stock. According to Zacks, “NexPoint Residential Trust, Inc. is engaged in acquiring, owning, operating and selectively developing multifamily properties. It operates primarily in the Southeastern United States and Texas. NexPoint Residential Trust, Inc. is based in Dallas, United States. “

Receive News & Ratings for Mistras Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mistras Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.